Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.72 |
| ▸ | MAOA | P21397 | 7/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | SDHA | P31040 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CALML3 | P27482 | 1/20 | 0.72 |
| ▸ | F10 | P00742 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1809644 | 0.90 | MAOB (0.59) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL15618756 | 0.89 | MAOB (0.65) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12126891 | 0.89 | MAOB (0.65) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL19512263 | 0.88 | MAOB (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL14706888 | 0.86 | MAOB (0.72) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL14276050 | 0.86 | MAOB (0.72) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5810297 | 0.85 | MAOB (0.58) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL12006736 | 0.85 | MAOB (0.74) | MAOBMAOAPTGS1SDHALMNA | |
| Acetic Acid SCHEMBL1338391 | 0.85 | MAOB (0.74) | MAOBMAOAPTGS1SDHALMNA | |
| Acetic Acid SCHEMBL1338393 | 0.85 | MAOB (0.74) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | HANGZHOU DIKE TECHNOLOGIES CO., LTD. (CN) | 2022-08-25 | — | — | US | disclosed |
| WO-2021031533-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | 杭州迪克科技有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-9376407-B2 | Process for preparation of Linezolid and its novel intermediates | LEE PHARMA LIMITED (IN) | 2016-06-28 | — | — | US | disclosed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014174522-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-10-30 | — | — | WO | disclosed |
| WO-2014045292-A1 | IMPROVED PROCESS FOR THE PREPARATION OF LINEZOLID INTERMEDIATE | SYMED LABS LIMITED (IN) | 2014-03-27 | — | — | WO | disclosed |
| WO-2013072923-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE LINEZOLID | CADILA HEALTHCARE LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | CYP3A5, SBDS, MLYCD | MAOB 951/4885MAOA 522/4885PTGS1 2907/4885 |
| US-20220267284-A1 | METHOD FOR SYNTHESIZING N-SUBSTITUTED PHENYL-5-HYDROXYMETHYL-2-OXAZOLIDINONE | CYP3A5, CYP1A2, CYP3A4 | MAOB 664/4885MAOA 638/4885PTGS1 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.